Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Month's Bonus Article 3 Stocks Under $5 With Strong Analyst Upside PotentialWritten by Chris Markoch. Article Published: 2/24/2026. 
Key Points - Grab Holdings is gaining analyst support as revenue growth and its first full year of profitability highlight long-term opportunity in Southeast Asia’s expanding digital economy.
- Vaxart offers speculative biotech upside with its oral vaccine platform targeting influenza, norovirus, and COVID-19, creating a high-risk, high-reward setup.
- ThredUp is positioned to benefit from the fast-growing resale market, with strong institutional ownership and industry forecasts pointing to sustained secondhand demand.
- Special Report: [Sponsorship-Ad-6-Format3]
At a time when many investors are rotating out of speculative penny stocks, others continue to embrace the risk-reward tradeoff. Stocks that trade for under $5 carry a higher level of risk: many of these companies are unprofitable, and some generate little to no revenue. In almost every case these are small-cap companies, and small-cap stocks have been under pressure in recent years. Even though the Russell 2000 is showing signs of strength, that improvement hasn't been broad-based across the small-cap sector. That could change in 2026 if the economic outlook continues to improve and capital flows back into speculative names. As with any segment of the market, though, quality matters. One way to filter for quality is to look for stocks that enjoy positive analyst sentiment. That's the case with these three names. Each allows an investor to start a meaningful position with a modest outlay while retaining the potential for significant upside over the next five years. Profitability Milestone Meets Long-Term Emerging Market Growth Emerging-market stocks are expected to be among the winners in 2026, but that hasn't been true so far for Grab Holdings Inc. (NASDAQ: GRAB), which is down about 15% year-to-date. Grab, based in Singapore, operates a super app that blends technology, e-commerce and fintech services. One reason for the stock's recent pullback is its proposed merger with Indonesian ride-hailing competitor GoTo. The deal is not final and could be affected by potential legislative changes in Indonesia that would limit earnings potential in that market. The company also came up slightly short on the top line in its Q4 2025 earnings report. That said, revenue was up 19% year-over-year (YOY), and the period marked the company's first full year of profitability. Analysts are forecasting roughly 120% earnings growth in the next 12 months. That helps explain why sentiment remains generally bullish. GRAB stock carries a consensus price target of $6.47, which would imply about 54% upside from the current price. High-Risk Biotech With Platform Potential Penny-stock investors often look to the biotechnology sector because it can offer asymmetric upside. One name to watch is Vaxart Inc. (OTCMKTS: VXRT), the only company on this list that meets the classic definition of a penny stock. At the time of writing, it traded just over $0.60 per share. VXRT lacks heavy analyst coverage, but the lone analyst rating issued in the past 12 months is a Buy with a $2 price target. It's not uncommon for analysts to skip coverage of some biotech firms. Vaxart is a clinical-stage company, meaning all of its candidates remain in clinical trials. The potential upside is clear: Vaxart is developing oral vaccines—primarily for influenza, norovirus and COVID-19. Beyond convenience and addressing needle aversion, the company says its platform may elicit a broader immune response that could provide wider protection. Institutional ownership of VXRT is modest at about 18%, but in terms of dollar volume recent inflows outnumber outflows by nearly 10:1, which is notable for a small-cap clinical-stage biotech. Resale Tailwinds Could Turn Today's Losses Into Tomorrow's Gains ThredUp Inc. (NASDAQ: TDUP) is down about 33% year-to-date in 2026, but a longer view shows the stock is up more than 66% over the past 12 months. That frames the recent drop more as a pullback during a period when investors are avoiding companies that aren't yet profitable. In ThredUp's case, the caveat "yet" may be important. The company runs an online consignment and thrift marketplace that is gaining traction with Gen Z consumers, reflected in revenue growth. In its most recent quarter, revenue rose 12.5% YOY. ThredUp cites a GlobalData 2025 market survey that forecasts the U.S. secondhand market's gross merchandise value growing at a compound annual growth rate (CAGR) of 9% through 2029. Institutional investors own an impressive 89% of TDUP. Measured in dollars, buying has recently outpaced selling roughly two-to-one, and in terms of the number of participants, buyers outnumber sellers about three-to-one. That said, short interest is around 17%, which can add near-term volatility. The consensus price target from six analysts is $12.50, implying more than 190% upside from the current price.
| 
